Valproic Acid · Regulatory label update

FDA supplemental approval: Valproic Acid (Labeling)

U.S. Food and Drug Administration · April 8, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a U.S. FDA supplemental approval for a labeling change to valproic acid 250 mg capsules, granted to BIONPHARMA on 8 April 2026. The record does not contain clinical trial results, efficacy data, or details of the labeling modification.

What was studied

Regulatory label update. United States (FDA jurisdiction).

Key findings

Safety

No clinical trial results, safety data, or efficacy measures are reported.

Who this may help

Clinicians should consult the updated product label for any new contraindications, warnings, dosing guidance, or safety information that prompted this regulatory action. This approval does not convey efficacy or comparative benefit data.

Plain-language summary

FDA supplemental approval for a labeling change to valproic acid; does not report clinical trial data or efficacy evidence.

Study design

As stated by the source record.

SettingUnited States (FDA jurisdiction)

Clinical bottom line

Caveats

Record does not specify what labeling change was approved.
No clinical trial results, safety data, or efficacy measures are reported.
Approval class and submission class indicate labeling revision only, not new indication or formulation.
Full prescribing information must be reviewed directly from FDA or manufacturer sources.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action; no study design reported.

Directness

insufficient

Labeling record; does not report clinical outcomes or trial data.

Consistency

insufficient

Single regulatory action; no comparative or replicate data provided.

Risk of bias

insufficient

Regulatory record; bias assessment not applicable to labeling approval.

Sample adequacy

insufficient

No clinical trial population or sample size reported in this record.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA073484. This is a regulatory action record, not a clinical study. Brand name: VALPROIC ACID. Active ingredient: VALPROIC ACID. Sponsor: BIONPHARMA. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-04-08. Products: VALPROIC ACID, CAPSULE, ORAL, VALPROIC ACID 250MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

BionpharmaValproic Acid